FTC puts hospital price disclosures under a harsher federal lens
The Federal Trade Commission is moving price transparency from a reporting exercise to an enforcement risk. FTC Chairman Andrew Ferguson sent warning letters to two dozen hospital operators, telling them that incomplete or misleading pricing disclosures could trigger scrutiny under federal consumer protection law as well as the broader regulatory framework already in place through CMS and HHS.
The clinical relevance is indirect but real: when patients cannot see credible prices, they cannot reliably compare care options before treatment, especially for planned procedures, imaging, and other shoppable services. In practical terms, opaque hospital pricing can function like a barrier to informed consent at the financial level, leaving families exposed to bills they never had a fair chance to anticipate.
The warning letters did not name the recipients, and the agency declined to release a list. Even so, the message was unmistakable. Hospitals are being told that posting something is not the same as posting something usable, and that a partial disclosure may be treated as misleading if it omits fees or other components that materially affect what a patient actually pays.
CMS rules are no longer the only benchmark hospitals face
For years, the main federal pressure point on hospital pricing came through CMS. The hospital price transparency rule, finalized in 2019, requires hospitals to publish standard charges, including negotiated rates with insurers, in two formats: a machine-readable file and a consumer-facing display of 300 shoppable services. Enforcement began in 2021, and CMS later added requirements intended to improve readability, accountability, and the context patients need to compare costs.
The FTC is now making clear that CMS compliance does not end the legal analysis. Ferguson described the CMS requirements as a “regulatory floor,” not a shield from the FTC Act. If a hospital withholds prices altogether, or publishes data that leaves out meaningful extra charges, the agency may view the disclosure as deceptive because it could mislead consumers into believing they know the total cost of care when they do not.
The enforcement posture matters because hospital price files have often been criticized for being difficult to navigate, inconsistent in format, or incomplete enough to blunt their usefulness. A machine-readable file full of gaps is not the same as a transparent price. When facility fees, ancillary charges, or other service-line costs are excluded, the resulting figure can understate the real economic burden of care and distort decisions made by patients, employers, and even referring clinicians trying to guide patients through elective treatment choices.
Incomplete pricing can create deceptive impressions for patients
At the center of the FTC’s concern is the difference between disclosure and clarity. Hospitals that publish only part of the cost picture may create a false sense of certainty. A patient comparing prices for a procedure might believe one facility is cheaper, only to learn later that additional charges materially change the total bill. In consumer protection terms, that gap can be treated as a deceptive omission if the missing information is important enough to alter a purchasing decision.
That is a familiar enforcement theory in other sectors, but its application to healthcare has special weight because care decisions are rarely made under ideal conditions. Patients often choose with limited time, limited clinical literacy, and limited bargaining power. Pricing information that is technically present but functionally confusing does little to address those asymmetries.
Hospitals also face a more complex compliance environment than many other industries. They are already navigating CMS obligations, insurer disclosure reforms finalized Monday by HHS, Labor, and Treasury, and the possibility that different agencies will judge transparency through different legal lenses. The newly finalized insurer rule is designed to strip away junk data and standardize file formats, reinforcing the administration’s broader push to make pricing data more readable and actionable.
Federal agencies are converging on the same accountability message
The FTC letters arrived alongside a separate federal push to strengthen insurer transparency reporting, and the overlap is not accidental. Together, the actions signal an effort to close the gaps that have allowed hospitals and payers to release pricing data that exists on paper but fails in practice. The policy theory is straightforward: when prices are visible, patients can shop more effectively, competition becomes less abstract, and downward pressure on costs may eventually follow.
Hospitals, however, have lagged behind expectations. PatientRightsAdvocate.org said in September that more than half of hospitals were still not fully compliant with the CMS hospital price transparency rule. CMS has fined 28 noncompliant hospitals since 2021, with roughly a third of those penalties issued after Trump returned to office at the start of last year. Those numbers suggest the problem has not been a lack of federal rules so much as weak adherence and uneven enforcement.
The new FTC posture raises the stakes further because it expands the consequences beyond CMS penalties alone. Hospitals now have to think not only about whether they satisfy the technical requirements of the CMS rule, but also whether their disclosures could survive a consumer protection challenge if patients are misled by what is omitted.
For health systems, that means compliance teams may need to look more carefully at the completeness of gross charges, negotiated rates, and any fees that shift the final bill upward. For patients, the immediate implication is simpler: the presence of a posted price should not be mistaken for a full price unless the disclosure actually captures the services and fees that shape the bill.
The regulatory pressure is likely to intensify as federal agencies continue to treat pricing transparency as an enforcement priority rather than a voluntary best practice. What remains unresolved is how aggressively the FTC will pursue hospitals that technically publish data but do so in ways that still leave consumers misled, and whether future actions will test the boundaries between administrative compliance and deceptive practice under federal law.